Influence of Dosage, Age, and Co-medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response

Research output: Contribution to journalArticle

Abstract

The influence of dosage, age, and co-medication on plasma topitamate (TPM) concentrations at steady state was investigated in 51 patients aged 3 to 30 years. All patients had chronic active epilepsy, and most were receiving concomitant medication with enzyme-inducing anticonvulsants (carbamazepine and phenobarbital). Plasma TPM concentrations were determined by a specific immunoassay in samples obtained before the morning dose. Thirty-five patients could be evaluated prospectively at different dose levels, and the relationship between plasma TPM concentration and dosage was linear over the assessed dose range (1.8 to 10.0 mg/kg) both in adults and in children. The influence of age on pharmacokinetic parameters could be assessed only for the 42 patients co-medicated with enzyme inducers. In these patients dose-normalized plasma TPM concentrations correlated positively with age (r = 0.59, P <0.0001), where apparent oral clearance values (CL/F) were inversely related to age (r = 0.73, P <0.0001). In particular, CL/F values in children aged less than 10 years (112 ± 82 mL/kg/h, mean ± SD, n = 14) were almost three times as high as those observed in patients aged >15 to 30 years (42 ± 16 mL/kg/h, n = 17), whereas the CL/F value in children aged 10 to 15 years (66 ± 22 mL/kg/h, n = 11) was intermediate between those found in the two other age groups. Patients not receiving enzyme-inducing AEDs showed lower CL/F values than did age- and gender-matched patients on enzyme-inducing co-medication. A preliminary evaluation of the relationship between plasma TPM concentration and therapeutic response could be made in 41 patients. No significant difference in drug concentration was detected between patients showing a greater than 50% reduction in seizure frequency compared with baseline (5.9 ± 2.2 μg/mL, n = 30) and those having no clinical improvement (5.2 ± 2.2 μg/mL, n = 11). Likewise, there was no consistent relationship between plasma TPM concentration and appearance of adverse effects. These results indicate that plasma TPM concentrations are linearly related to dosage both in adults and in children and that children aged

Original languageEnglish
Pages (from-to)700-708
Number of pages9
JournalTherapeutic Drug Monitoring
Volume25
Issue number6
DOIs
Publication statusPublished - Dec 2003

Keywords

  • Children
  • Epilepsy
  • Pharmacokinetics
  • Therapeutic drug monitoring
  • Topiramate

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology

Fingerprint Dive into the research topics of 'Influence of Dosage, Age, and Co-medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response'. Together they form a unique fingerprint.

  • Cite this